BioMarin Pharmaceutical | BMRN - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 172.31M 174K 2026-09
Agios Pharmaceuticals USD 59.6M 264K 2026-06
Alnylam Pharmaceuticals USD 133.88M 141K 2026-09
Amgen USD 541M 0 2026-09
Bayer EUR 982.42M 0 2026-09
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Gilead Sciences USD 1.24B 1000K 2026-06
Incyte USD 200.98M 1.03M 2026-06
Insmed USD 218.28M 1.76M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 101.3M 750K 2026-09
PTC Therapeutics USD 83.33M 445K 2026-06
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 796.77M 1.15M 2026-06
Sanofi EUR 1.2B 2.15M 2026-06
Sarepta Therapeutics USD 107.23M 1.61M 2026-09
Ultragenyx Pharmaceutical USD 98.6M 300K 2026-06
United Therapeutics USD 42.38M 295K 2026-09
Vertex Pharmaceuticals USD 253.5M 200K 2026-09